On November 11, 2025, Sanofi and Regeneron announced that the FDA accepted for priority review its supplemental biologics license application ...
Seattle health officials and Harborview Medical Center staff are investigating the possibility of a fungal infection outbreak ...
Schooling ourselves to protect our present and secure our future - The ...
ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...
TARRYTOWN/PARIS - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi announced Friday that their drug Dupixent (dupilumab) demonstrated significant improvements in patients with allergic fungal ...
Sanofi & Regeneron’s Dupixent pivotal study meets all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis: Paris Monday, November 10, ...
ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...
Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion and nasal polyps in patients aged 6 years ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best gene-editing stocks to buy according to hedge funds.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback